Tag Archive for: Parkinson’s

Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy

• Developing novel therapeutics which enhance the removal of dysfunctional mitochondria, promoting cell health and function • MTX325 is a potentially disease-modifying treatment for Parkinson’s Disease with clinical trial due to start imminently • Backed by blue chip international investors Cambridge, UK – March 14, 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech […]

Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease

Copenhagen, Denmark, 23rd January 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the Company has been awarded a grant (MJFF-024128) worth c.US$873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease. The […]

Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference

CAMBRIDGE, UK, 10 October 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that its Chief Scientific Officer, Dr Paul Thompson, will give an oral presentation on its experimental drug candidate MTX325 at the 15th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference on October 19, 2023, in New York. Dr […]

Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference

CAMBRIDGE, UK, 10 October 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that its Chief Scientific Officer, Dr Paul Thompson, will give an oral presentation on its experimental drug candidate MTX325 at the 15th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference on October 19, 2023, in New York. Read […]

Muna Therapeutics Awarded $4.9M Grant from The Michael J. Fox Foundation for Parkinson’s Research Supports Development of Disease Modifying Therapy for Parkinson’s Disease

Copenhagen, Denmark and Boston, US, 11th October 2022 – Muna Therapeutics (Muna), a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease and other neurodegenerative disorders, announced today that it has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).  Read more…